Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ghrh receptor siRNA
- Development stage
- Preclinical
- Lead developer
- Chang Gung Memorial Hospital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
GHRH receptor siRNA is a small interfering RNA (siRNA) designed to silence the expression of the growth hormone-releasing hormone receptor (GHRHR). In preclinical research, particularly in endometrial cancer models, it serves as a molecular tool to elucidate the signaling pathways of growth hormone-releasing hormone (GHRH) and its antagonists. By specifically knocking down the GHRH receptor, researchers have demonstrated that the inhibitory effects of GHRH antagonists on cancer cell motility and the expression of epithelial-mesenchymal transition (EMT) markers, such as Twist and N-Cadherin, are mediated through this receptor. This knockdown approach is essential for validating that the observed therapeutic effects of GHRH-targeted compounds are indeed dependent on the presence and activity of the GHRH receptor.
- Other names
- human GHRH receptor siRNAGHRHR siRNA
02
Targets
GHRHR (Growth hormone-releasing hormone receptor)
Beyond the preview
Go deeper on ghrh receptor siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ghrh receptor siRNA.